LDB3

Across TCGA pan-cancer cohorts, LDB3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LDB3 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LDB3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LDB3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where LDB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.903	0.363	.001	44	view →
LUAD	DFS	Median	II,III,IV	0.723	0.983	.006	12	view →
PDAC	DFS	Median	All	0.869	0.726	.011	8	view →
LSCC	OS	Median	II,III,IV	0.902	1.000	.020	5	view →
HNSC	DFS	Quartile	III,IV	0.812	0.491	.016	3	view →
GBM	DFS	Tertile	All	0.252	0.433	.045	2	view →
UCEC	DFS	Tertile	All	0.944	0.840	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LDB3–CCRCC (DFS)

Open the CCRCC breakdown →